Ibex Wealth Advisors Sells 53,231 Shares of Gilead Sciences, Inc. $GILD

Ibex Wealth Advisors lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 77.6% in the first quarter, HoldingsChannel.com reports. The fund owned 15,323 shares of the biopharmaceutical company’s stock after selling 53,231 shares during the quarter. Ibex Wealth Advisors’ holdings in Gilead Sciences were worth $2,136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. State Street Corp grew its holdings in Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock worth $7,393,921,000 after purchasing an additional 1,151,213 shares during the period. Price T Rowe Associates Inc. MD increased its position in Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after buying an additional 1,195,269 shares during the last quarter. Bank of America Corp DE raised its stake in Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after buying an additional 3,046,688 shares during the period. Finally, Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $2,617,152,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,000 shares of company stock valued at $10,824,500 over the last three months. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on GILD. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $133.00 to $155.00 in a research note on Monday. Morgan Stanley decreased their price objective on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday. Leerink Partners dropped their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Finally, Rothschild & Co Redburn reduced their target price on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $159.04.

Gilead Sciences Stock Down 0.7%

GILD stock opened at $134.84 on Friday. Gilead Sciences, Inc. has a 52 week low of $107.75 and a 52 week high of $157.29. The business has a 50-day simple moving average of $129.76 and a 200 day simple moving average of $134.99. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a market cap of $167.41 billion, a PE ratio of 18.37 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the company posted $1.81 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.